APODDC

We’ll be hosting Clinical Trial Design webinars in 2023! Follow us to be kept up to date. 📊🧑🏻‍💻

[Herbert Loong, MBBS, FASCO @herbloong]

📢 #Happy to share w/ #LCSM community! After 3+ years of work, we are pleased to share our #cost_effectiveness modelling for #lungcancer 🫁 #screening 🏥📸 in both #high-risk populations determined by both #smoking & #non-smoking risk factors e.g. family history for an entire community.

Taking #hongkong 🇭🇰 as an example of our #EastAsia region w/ specific lung cancer #epidemiology and #molecularcharacteristics, we have shown that #ICER for high risk individuals based on factors not associated with smoking is even lower.

This is the first study of modelling for an entire health system catering for both high risk groups. This calls for #government & other #stakeholders to push forward #territorywide #lungcancer screening for ALL #highrisk individuals - regardless of smoking history.

Further details can be found here: https://t.co/hZsyM3Sdu1

@CarlosWongHKU @mollylisc @CUHKMedicine @hkumed @HKU_D24H @IASLC @APCLC_2023 @apoddc @LungPolicy #NELSON #TALENT #PublicHealth

[ESMO Open @ESMO_Open]

Safety of tarlatamab with 6-8h outpatient vs 48-h inpatient monitoring during C1: DeLLphi-300 ph1 substudy in @ESMO_Open. Outpatient monitoring feasible, same CRS rate, most managed w/o hospitalization/ER visit. Anticipate&monitor AEs in educated pts is🔑. https://t.co/7Gofv69Psf

[ESMO - Eur. Oncology @myESMO]

Newly published ESMO recommendations provide roadmap for the implementation of molecular tumour boards in clinical practice.
Discover the key focus areas to optimise #PrecisionOncology
Read via #ESMODailyReporter: https://t.co/vd2FW8ZVBC

@BenWestphalen @Annals_Oncology

[Herbert Loong, MBBS, FASCO @herbloong]

Wonderful crew of @myESMO #ESMORarecancer25 #YOCasesDiscussion session! Definitely not-so-young oncologists including #myself are also welcome.

Great cases discussed and thanks everyone for contributing to lively discussions.

@pawel_sobczuk @DrLizConnolly @Robertasanfili @RobinL_Jones @haileykcarroll and many others. #sarcoma #CTOSTweeTOS

[Lillian Siu @lillian_siu]

It's pleasure coauthoring this @Cancer_Cell commentary with 2 talented drug development fellows #gregoire marret and #mercedes herrera @pmcancercentre - "Turning the Kaleidoscope: Innovations shaping the future of clinical trials design"
https://t.co/cFWN5kUGVT

[APODDC @apoddc]

@HHorinouchi @JSMO_official @JTOonline @OncoAlert Amazing work by our #Asian colleagues!

[Hidehito HORINOUCHI @HHorinouchi]

🔥 @JCO_ASCO 🆙
✅LIBRETTO-001 final: Selpercatinib in RET Fusion–Positive Non–Small Cell Lung Cancer
🎯mOS 47.6 (pretreated pts), not reached (treatment-naïve)
👥 @GautschiOliver
#LCSM @OncoAlert

[Stephanie Saw @stephanieplsaw]

Delighted to share our review paper on ADCs in NSCLC with AGA is out! Very timely given the anticipated data readouts this year. Such an honour to be a part of this awesome team, special thanks to @g_mountzios and @JordiRemon for leading this 🙌🏻

[Brian Van Tine @bvantine1]

It's ok at #CTOS2024 to drag me to your poster to pitch your science for Clinical Cancer Research, it the most inspiring thing i get to do!!

[Clinical Cancer Research @CCR_AACR]

Phase 2 Study: Trametinib Treatment of Epithelioid Hemangioendothelioma. https://t.co/iWLRIHDpJ5

[Herbert Loong, MBBS, FASCO @herbloong]

Thanks @drkiwicj @drkiwikate @anmwongNZ @cameroncologist #DaisyMak (who needs to get on Twitter! 😆) & all my other 🇳🇿 #oncology friends @NzsOncology for your invitation & hospitality. Amazing talks & discussions throughout the conference. Perfect forum to build collaborations.

@ASCO #InternationalAffairsCommittee @IASLC #LCSM #Sarcoma @CUHKMedicine #CUHKSarcoma @apoddc @APCLC_2023 #precisiononcology @OncoAlert

[Annie Wong 黃毅敏 @anmwongNZ]

Thank you superstar @herbloong for being a keynote speaker @NzsOncology

Timely discussions on accessibility/ cost savings for #PrecisionOncology

Need personalise a model for 🇳🇿 too!

@apoddc @TeWhatuOra @cancer_agency

[WinetteVanDerGraaf @Winette_vdGraaf]

Thank you @jeanyvesblay for your excellent talk at the @cddf_eu - @EORTC workshop #RareCancers

You last slides summarized it so well

[Herbert Loong, MBBS, FASCO @herbloong]

Thanks @drdgoldstein for coming all the way from 🇮🇱 to 🇭🇰 to share insights and experiences in #pharmacoeconomics. Organised by #ProfVivianLee and colleagues of @cuhkpharmacy Very engaged workshop together with stakeholders from #academia, #industry, #patientsrepresentatives and the #HospitalAuthority @CUHKMedicine @hkumed

[APODDC @apoddc]

📢Announcement: Join us at our 1st #APODDCForum2024 where we discuss about the Regulatory Harmonisation for Oncology Clinical Trials & Therapeutics Registration in the APAC Region📷 Sign up now via https://t.co/lRCP9HyyTG!📧 More details on our LinkedIn Page!

[Herbert Loong, MBBS, FASCO @herbloong]

📢 T-28 days to our 6th @CUHKMedicine #CUHKSarcoma Masterclass in #hongkong 🇭🇰! We are looking forward to welcoming #international and #local faculties to our annual event. Congrats to 8 overseas attendees who have been #awarded #travelgrants to #present and #attend this year's course! Details to follow! @saxotomy @irhkch @val_yang @cuhksurgery @CUHKOrtho @ctosociety

[Aɴᴛᴏɴɪᴏ Pᴀssᴀʀᴏ @APassaroMD]

Truly honored to have been invited to speak on EGFR-mut NSCLC at the National Cancer Center in Singapore by Daniel Tan and his incredible team. Grateful for the opportunity to share insights and collaborate on such an important topic @danieltanmd @SingHealthSG @pankajpanda86 @reggie_hoo @drkevin_chua_lm @stephanieplsaw

[Herbert Loong, MBBS, FASCO @herbloong]

Congrats @jeanyvesblay & colleagues of #FrenchSarcomaGroup for completing study of #6vs3years of #adjuvant #imatinib 💊i n pts w/ #highrisk #GISTs. Presented at @myESMO @AACR #virtualplenary over last #2days with #specific discussions from #APAC #discussants as well! #CUHKSarcoma #CTOSTweeTOS @saxotomy @GistLab @Liferaftgroup @ctosociety Recordings available on #OncologyPro!

[ESMO - Eur. Oncology @myESMO]

#ESMOVirtualPlenary: And straight after the first abstract session tomorrow (9/5), remain connected to discover more promising results on #GIST. 📢 A randomised study of 6 vs 3 years of adjuvant imatinib in pts w/ localised GIST at high risk of relapse. https://t.co/L4xDX1oBU2 @jeanyvesblay @hgelderblom @herbloong @saxotomy

[Rashid Lui 雷諾信 @RashidLui]

Prof Jacky Lam sharing at the @CUHKMedicine Department of Clinical Oncology Academic Meeting on liquid biopsy for early cancer detection

#oncology